Covid-19 roundup: Pfizer, BioNTech set new production quota for vaccine at 2B doses in 2021; New data show IL-6 inhibitor could be effective treatment after all
Pfizer and BioNTech are well on their way to a global rollout of their mRNA-based Covid-19 vaccine, BTN162b2. Even with logistical challenges hampering that plan, Germany’s BioNTech is planning a vast expansion of its production capacity in the coming year.
BioNTech plans to churn out more than 2 billion doses of BNT162b2 in 2021, far outpacing the 1 billion doses tied up in supply commitment around the globe, the company said in a virtual presentation at the virtual JP Morgan Healthcare Conference.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.